We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aslan

News List

ASLAN presents Ph2 study data for Varlitinib tested on BTC patients biospectrumasia
September 20, 2019
Enrolment in a global pivotal study of varlitinib in second line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in December 2018 and topline data is expected in the second half of 2019.
ASLAN signs agreement with Korean Gastric Cancer group biospectrumasia
May 13, 2019
K-MASTER, operated by Korea University, is funded by the South Korean government
ASLAN signs agreement with Korean Gastric Cancer group biospectrumasia
May 12, 2019
K-MASTER, operated by Korea University, is funded by the South Korean government
FDA grants orphan drug status to ASLAN’s treatment for AML biospectrumasia
August 21, 2018
ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML.
ASLAN submits authorisation application with HSA biospectrumasia
July 04, 2018
The single ascending dose study will recruit healthy volunteers and the multiple ascending dose study will recruit patients with atopic dermatitis.